(Q36918131)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Protein kinases as targets for cancer treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Justin Stebbing

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Constantinos E Vorgias

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Uwe Knippschild

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

1005-1016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics, 2002

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Protein kinase inhibitors as a therapeutic modality

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Kinomics-structural biology and chemogenomics of kinase inhibitors and targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Archaeal protein kinases and protein phosphatases: insights from genomics and biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Human members of the eukaryotic protein kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Signaling--2000 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Protein kinases and phosphatases as therapeutic targets in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Switching signals on or off by receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Receptor tyrosine kinases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Autoinhibition of Bcr-Abl through its SH3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Tyrosine kinase receptors as attractive targets of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

21 January 2018

Targeting tumor cells

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Panitumumab: in the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Tyrosine kinases as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Tyrphostins--potential antiproliferative agents and novel molecular tools

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Mechanisms of action of flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Phase II study of flavopiridol in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

21 January 2018

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

PI3K in lymphocyte development, differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

The Hsp70 and Hsp60 chaperone machines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Molecular chaperones in cellular protein folding

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.1005

10.2217/14622416.8.8.1005

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17716234%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference